Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics

Cell Research

Volumn 25, Issue 6, 2015, Pages 707-725

  Koo, Gi Bang ^a   Morgan, Michael J ^b   Lee, Da Gyum ^a   Kim, Woo Jung ^a   Yoon, Jung Ho ^a   Koo, Ja Seung ^c   Kim, Seung Il ^c   Kim, Soo Jung ^d   Son, Mi Kwon ^d   Hong, Soon Sun ^d   Levy, Jean M Mulcahy ^e   Pollyea, Daniel A ^b   Jordan, Craig T ^b   Yan, Pearlly ^f   Frankhouser, David ^f   Nicolet, Deedra ^f,g   Maharry, Kati ^f,g   Marcucci, Guido ^f   Choi, Kyeong Sook ^a   Cho, Hyeseong ^a   Thorburn, Andrew ^b   Kim, You Sun ^a   more..

^a Ajou University School of Medicine   (South Korea)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Yonsei University College of Medicine   (South Korea)

^d Inha University School of Medicine   (South Korea)

^e Children's Hospital Colorado   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g MAYO CLINIC   (United States)

Author keywords

chemotherapy; hypomethylating agents; MLKL; programmed necrosis; RIP3 (RIPK3)

Indexed keywords

ANTINEOPLASTIC AGENT; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK3 PROTEIN, HUMAN;

ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL SURVIVAL; DEFICIENCY; DNA METHYLATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; HUMAN; METABOLISM; MOUSE; NECROSIS; NUDE MOUSE; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL SURVIVAL; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NECROSIS; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930374188     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2015.56     Document Type: Article

References (53)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
2. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11:700-714.
3. Vanlangenakker N, Vanden Berghe T, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 2012; 19:75-86.
4. Morgan M, Liu Z. Programmed cell death with a necrotic-like phenotype. BioMol Concepts 2013; 4:259-275.
5. Kaiser WJ, Upton JW, Long AB, et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 2011; 471:368-372.
6. Oberst A, Dillon CP, Weinlich R, et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011; 471:363-367.
7. Zhang H, Zhou X, McQuade T, Li J, Chan FK, Zhang J. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 2011; 471:373-376.
8. Lu JV, Weist BM, van Raam BJ, et al. Complementary roles of Fas-associated death domain (FADD) and receptor interacting protein kinase-3 (RIPK3) in T-cell homeostasis and antiviral immunity. Proc Natl Acad Sci USA 2011; 108:15312-15317.
9. Bonnet MC, Preukschat D, Welz PS, et al. The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation. Immunity 2011; 35:572-582.
10. Gunther C, Martini E, Wittkopf N, et al. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 2011; 477:335-339.
11. Welz PS, Wullaert A, Vlantis K, et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011; 477:330-334.
12. Moriwaki K, Chan FK. RIP3: a molecular switch for necrosis and inflammation. Genes Dev 2013; 27:1640-1649.
13. Linkermann A, Brasen JH, Darding M, et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA 2013; 110:12024-12029.
14. Kaiser WJ, Upton JW, Mocarski ES. Viral modulation of programmed necrosis. Curr Opin Virol 2013; 3:296-306.
15. Zhang DW, Shao J, Lin J, et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325:332-336.
16. He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137:1100-1111.
17. Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137:1112-1123.
18. Zhao J, Jitkaew S, Cai Z, et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci USA 2012; 109:5322-5327.
19. Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148:213-227.
20. Wu J, Huang Z, Ren J, et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res 2013; 23:994-1006.
21. Murphy JM, Czabotar PE, Hildebrand JM, et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 2013; 39:443-453.
22. Cai Z, Jitkaew S, Zhao J, et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 2014; 16:55-65.
23. Chen X, Li W, Ren J, et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res 2014; 24:105-121.
24. Wang H, Sun L, Su L, et al. Mixed lineage kinase domainlike protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell 2014; 54:133-146.
25. Dondelinger Y, Declercq W, Montessuit S, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep 2014; 7:971-981.
26. Tenev T, Bianchi K, Darding M, et al. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011; 43:432-448.
27. Dondelinger Y, Aguileta MA, Goossens V, et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ 2013; 20:1381-1392.
28. Cook WD, Moujalled DM, Ralph TJ, et al. RIPK1-and RIPK3-induced cell death mode is determined by target availability. Cell Death Differ 2014; 21:1600-1612.
29. Kim YS, Morgan MJ, Choksi S, Liu ZG. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell 2007; 26:675-687.
30. Ventura JJ, Cogswell P, Flavell RA, Baldwin AS Jr, Davis RJ. JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev 2004; 18:2905-2915.
31. Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4:313-321.
32. Li JX, Feng JM, Wang Y, et al. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis 2014; 5:e1278.
33. Veeck J, Noetzel E, Bektas N, et al. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol Cancer 2008; 7:83.
34. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41:178-186.
35. Ghoshal K, Datta J, Majumder S, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005; 25:4727-4741.
36. Jezequel P, Campone M, Gouraud W, et al. bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat 2012; 131:765-775.
37. Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-? feedforward signaling. Cell 2011; 145:92-103.
38. Feoktistova M, Geserick P, Kellert B, et al. cIAPs block ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011; 43:449-463.
39. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114:181-190.
40. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004; 18:1272-1282.
41. Sosna J, Voigt S, Mathieu S, et al. TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct routes to programmed necrotic cell death. Cell Mol Life Sci 2014; 71:331-348.
42. Kasof GM, Prosser JC, Liu DR, Lorenzi MV, Gomes BC. The RIP-like kinase, RIP3, induces apoptosis and NF-?B nuclear translocation and localizes to mitochondria. FEBS Lett 2000; 473:285-291.
43. Newton K, Sun XQ, Dixit VM. Kinase RIP3 is dispensable for normal NF-?Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and toll-like receptors 2 and 4. Mol Cell Biol 2004; 24:1464-1469.
44. Sun XQ, Lee J, Navas T, Baldwin DT, Stewart TA, Dixit VM. RIP3, a novel apoptosis-inducing kinase. J Biol Chem 1999; 274:16871-16875.
45. Cowan LA, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics 2010; 2:71-86.
46. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011; 22:1736-1747.
47. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.
48. Pawitan Y, Bjohle J, Amler L, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005; 7:R953-R964.
49. Weigelt B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005; 65:9155-9158.
50. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25:1239-1246.
51. Chanrion M, Negre V, Fontaine H, et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 2008; 14:1744-1752.
52. Loi S, Haibe-Kains B, Desmedt C, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008; 9:239.
53. Marcucci G, Yan P, Maharry K, et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol 2014; 32:548-556.